John B. Hawken
Vorstandsvorsitzender bei Immutep SAS
Aktive Positionen von John B. Hawken
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
Immutep SAS
 Immutep SAS Pharmaceuticals: MajorHealth Technology Immutep SAS specializes in biotechnology research and development. It develops immunotherapy treatments for cancer and autoimmune diseases. The company was founded by Frédéric Triebel on October 17, 2001 and is headquartered Orsay, France. | Vorstandsvorsitzender | 02.12.2003 | - |
| Vorsitzender | 02.12.2003 | 10.04.2010 |
Karriereverlauf von John B. Hawken
Ehemalige bekannte Positionen von John B. Hawken
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
Aptanomics SA
 Aptanomics SA Pharmaceuticals: MajorHealth Technology Aptanomics SA discovers and develops new drugs in major markets of unmet medical need. Its proprietary discovery engine, based on peptide aptamers, delivers a regular flow of new hits against relevant industrial targets. Aptanomics offers opportunities for drug discovery collaborations leveraging the peptide aptamer technology to identify new druggable sites and screen for small molecule hits. The company was founded by Roger Brent, Pierre Colas and Johm B. Hawken in 2001 and is headquarters in Lyon, France | Corporate Officer/Principal | - | - |
Ausbildung von John B. Hawken
| University of Oxford | Undergraduate Degree |
| INSEAD | Masters Business Admin |
Statistik
International
| Frankreich | 4 |
| Vereinigtes Königreich | 2 |
Operativ
| Undergraduate Degree | 1 |
| Masters Business Admin | 1 |
| Chief Executive Officer | 1 |
Sektoral
| Consumer Services | 3 |
| Health Technology | 3 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Private Unternehmen | 2 |
|---|---|
Immutep SAS
Immutep SAS Pharmaceuticals: MajorHealth Technology Immutep SAS specializes in biotechnology research and development. It develops immunotherapy treatments for cancer and autoimmune diseases. The company was founded by Frédéric Triebel on October 17, 2001 and is headquartered Orsay, France. | Health Technology |
Aptanomics SA
Aptanomics SA Pharmaceuticals: MajorHealth Technology Aptanomics SA discovers and develops new drugs in major markets of unmet medical need. Its proprietary discovery engine, based on peptide aptamers, delivers a regular flow of new hits against relevant industrial targets. Aptanomics offers opportunities for drug discovery collaborations leveraging the peptide aptamer technology to identify new druggable sites and screen for small molecule hits. The company was founded by Roger Brent, Pierre Colas and Johm B. Hawken in 2001 and is headquarters in Lyon, France | Health Technology |
- Börse
- Insiders
- John B. Hawken
- Erfahrung
